SCHEMBL5924922

SCHEMBL5924922

COc1cccc(-c2cc(C(=O)O)cc(-c3cccc(OC)c3)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP1 P07148 1/20 0.61
CYP1A1 P04798 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2E1 P05181 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C8 P10632 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2A6 P11509 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP4B1 P13584 1/20 0.58
CYP2B6 P20813 1/20 0.58
CYP3A5 P20815 1/20 0.58
CYP2A7 P20853 1/20 0.58
CYP3A7 P24462 1/20 0.58
CYP2F1 P24903 1/20 0.58
CYP2C18 P33260 1/20 0.58
CYP2C19 P33261 1/20 0.58
CYP2J2 P51589 1/20 0.58
CYP4F2 P78329 1/20 0.58
CYP4F8 P98187 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254012 0.91 STIM1 (0.62) FABP1HSD17B2KMOSTIM1ORAI1
SCHEMBL16195497 0.91 DHODH (0.66) FABP1RXRAKMOSTIM1ORAI1
SCHEMBL4179829 0.86 RXRA (0.67) FABP1CYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL505652 0.86 RXRA (0.72) CYP2C8RXRAHSD17B2STIM1ORAI1
SCHEMBL30278441 0.86 RXRA (0.72) CYP2C8RXRAHSD17B2STIM1ORAI1
SCHEMBL14150399 0.84 RXRA (0.69) FABP1CYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL30420728 0.84 RXRA (0.69) FABP1CYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL2556922 0.84 FABP1 (0.56) FABP1CYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL29572748 0.83 RXRA (0.67) FABP1CYP1A1CYP1A2CYP2E1CYP3A4
SCHEMBL15275756 0.83 CYP11B1 (0.57) FABP1CYP1A2CYP3A4RXRAHSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122184-A1 Cyanomethyl derivatives as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed
US-20050288336-A1 Cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-12-29 US disclosed
EP-1569954-A1 CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-09-07 EP disclosed
WO-2004052921-A1 CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122184-A1 Cyanomethyl derivatives as cysteine protease inhibitors CTSF, CTSB, CTSK FABP1 2292/4885CYP1A1 2248/4885CYP1A2 2375/4885
US-20050288336-A1 Cysteine protease inhibitors CTSF, CTSS, CTSB FABP1 1087/4885CYP1A1 2988/4885CYP1A2 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.